RxDoctor Payments Data

Michael Roberts, MD

Internal Medicine · Decatur, ALNPI 1578577615

Payments from drug & device makers

$423in general payments, 2019–2025

Across 24 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$156
  • Astellas Pharma US Inc$134
  • GSK$31
  • Abbott$27
  • Johnson & Johnson$19
  • Amarin Pharma, Inc.$14
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$32376%
  • Education$10024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$423 in reported general payments places this provider in the 50th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$124,999
Medicare patients
306
Services billed
1,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$187,887
OzempicSemaglutide122$134,870
TrulicityDulaglutide61$63,746
FarxigaDapagliflozin Propanediol64$39,666
XareltoRivaroxaban41$35,925
LinzessLinaclotide55$32,482
MounjaroTirzepatide25$29,899
JanuviaSitagliptin Phosphate37$29,817
JardianceEmpagliflozin39$29,390
Tresiba Flextouch U-100Insulin Degludec35$22,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,138
MyrbetriqMirabegron39$20,446
EntrestoSacubitril/Valsartan31$20,195
Fiasp FlextouchInsulin Aspart (Niacinamide)12$13,877
SymbicortBudesonide/Formoterol Fumarate55$13,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$134,870122 claims
Johnson & JohnsonXarelto$19$35,92541 claims
AbbVieLinzess$156$32,48255 claims
GSKTrelegy Ellipta$31$21,13825 claims
Astellas Pharma US IncMyrbetriq$134$20,44639 claims
NovartisEntresto$13$20,19531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →